Rise Advisors’s Transmedics TMDX Stock Holding History

Rise Advisors’s Portfolio TMDX Stock Details TMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-579	Closed	-$48.6K	–	693
2023 Q2	$48.6K	Hold	579	–	–	0.04%	148
2023 Q1	$43.8K	Hold	579	–	–	0.03%	165
2022 Q4	$35.7K	Hold	579	–	–	0.03%	179
2022 Q3	$24K	Hold	579	–	–	0.02%	221
2022 Q2	$18K	Buy	+579	New	+$15.4K	0.02%	255

Other funds holding TMDX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Rise Advisors's TMDX Position: Q3 2023 in Review

Rise Advisors sold out of Transmedics (TMDX) in Q3 2023, closing a stake of 579 shares — an estimated $48.6K sold.

Rise Advisors first reported a position in TMDX in Q2 2022 and held it in 5 quarters. The position peaked at $48.6K in Q2 2023. 221 funds tracked by Wall St. Rank hold TMDX as of Q3 2023.

Rise Advisors reported no remaining Transmedics position as of Q3 2023 after selling out during the quarter.
Rise Advisors sold 579 Transmedics shares in Q3 2023, an estimated $48.6K.
Rise Advisors first reported a position in Transmedics in Q2 2022 and held it in 5 quarters.
Rise Advisors's Transmedics position peaked at $48.6K in Q2 2023.
221 funds tracked by Wall St. Rank held Transmedics as of Q3 2023.

Based on Rise Advisors's 13F filing for Q3 2023, filed 10 Oct 2023.